Browse the evidence

Dulaglutide, subcutaneous semaglutide, and tirzepatide exhibit comparable risks of severe gastrointestinal adverse events (including acute pancreatitis, biliary disease, bowel obstruction, gastroparesis, and severe constipation) in adults with type 2 diabetes.

If you are choosing between dulaglutide, semaglutide, or tirzepatide for type 2 diabetes, do not expect a significant difference in the risk of serious stomach problems (like pancreatitis or bowel obstruction) between them. They all carry a similar, low risk of severe GI events, though mild nausea or diarrhea is common with all. Your choice should likely be based on efficacy (weight loss/glycemic control), cost, and tolerability of mild side effects rather than fear of severe GI complications.

There are significant research gaps regarding the effectiveness of nutritional interventions for underrepresented populations, specifically women, older adults, and Asian populations.

Be aware that most research on muscle hypertrophy interventions focuses on men and Western populations. If you are a woman, older adult, or from an Asian background, the optimal nutritional strategy may differ, and you should consult a professional for personalized guidance.

Obesity is a primary chronic disease driven largely by genetic predisposition, amplified by caloric intake and decreased energy expenditure, requiring recognition as a disease for proper insurance coverage and management.

Stop blaming yourself or your patients for obesity. It is a primary disease with strong genetic components. This recognition is the first step to getting proper insurance coverage and medical treatment, not just lifestyle advice.

Using external momentum (cheat repetitions) during single-joint upper body resistance training produces muscle hypertrophy equivalent to strict technique, despite generating significantly higher volume load.

If you are doing single-joint exercises like bicep curls or tricep pushdowns, you don't need to be rigid about 'strict' form to maximize muscle growth. Using 'cheat' reps (adding momentum) allows you to lift more total volume, which resulted in the same muscle growth as strict reps in this study. However, be cautious of joint stress, especially in your back and hips, as momentum can increase injury risk. Use this technique strategically, perhaps at the end of a set, rather than for every rep, to balance gains with safety.

Providing free, convenient gym access to employees does not significantly improve weight loss outcomes compared to standard behavioral interventions, as gym usage remains low and weight loss is driven by the behavioral program rather than facility proximity.

Buying a gym membership or working near a gym will not automatically make you lose weight. In this study, people who worked near the gym used it more often, but they didn't lose more weight than those who didn't. Weight loss came from the behavioral program (diet/lifestyle coaching), not the gym access itself. Focus on the behavioral changes (diet, activity habits) rather than just buying access to facilities.

High carbohydrate intake (highest tertile, median 59.3% energy) is associated with increased MRI-detected vascular brain injury (covert brain infarcts and white matter hyperintensities) and lower cognitive scores (MoCA and DSST) in middle-aged adults.

If you are middle-aged and concerned about brain health, look at your overall macronutrient balance. High carbohydrate intake (over 59% of calories) is linked to more silent brain injuries and lower cognitive scores. Try shifting some of those carbohydrates to healthy fats, like those found in nuts, olive oil, or fish, which were associated with better brain health in this study.

Bariatric surgery (RYGB or SG) improves peripheral insulin sensitivity only after substantial weight loss (>30%) is achieved at 1 year, whereas low-calorie diet (LCD) fails to improve insulin sensitivity despite initial weight loss, indicating that the magnitude of weight loss, not the surgical mechanism itself, drives late-stage insulin sensitivity improvements.

If you undergo bariatric surgery, do not expect immediate improvements in insulin sensitivity. The metabolic benefits, such as improved insulin sensitivity, typically take about a year to manifest and are directly tied to the amount of weight you lose. If you do not lose significant weight, your insulin sensitivity may not improve, regardless of the surgery type.

Obesity promotes cancer development by increasing DNA damage and impairing DNA repair mechanisms, while simultaneously activating pro-survival signaling pathways that prevent the elimination of damaged cells.

Maintaining a healthy weight is a critical strategy for reducing cancer risk, not just for metabolic health. Obesity creates a biological environment that damages DNA and prevents the body from fixing those damages, while also protecting damaged cells from dying. Weight management interventions should be viewed as a direct cancer prevention strategy.

Periconceptional exposure to GLP-1 receptor agonists (liraglutide or semaglutide) is associated with an increased risk of preterm birth, but this risk is confined to women using the medication for diabetes treatment and is not observed in women using it for weight management.

If you are using a GLP-1 medication (like Ozempic or Saxenda) and planning pregnancy, talk to your doctor. If you have diabetes, the increased risk of early delivery is likely due to the diabetes, not the drug, so managing your blood sugar is key. If you are using it for weight loss, current large-scale data shows no increased risk of early delivery, which may help alleviate anxiety about inadvertent exposure.

Current herbal anti-obesity clinical trials frequently fail to adhere to international pharmaceutical guidelines, particularly regarding study duration, lifestyle modifications, and safety monitoring.

When evaluating herbal weight loss studies, be aware that many do not follow the same rigorous standards as pharmaceutical trials. Look for studies that include lifestyle modifications, adequate duration, and safety monitoring, as these are often missing.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, provides vasculoprotective and anti-atherosclerotic benefits by stimulating endothelial progenitor cell mobilization, enhancing nitric oxide synthase activity, and suppressing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6).

If you have Type 2 Diabetes or obesity with cardiovascular risk factors, Tirzepatide is not just a weight-loss drug. It actively protects your blood vessels by improving endothelial function and reducing inflammation. The standard protocol starts at a low dose (2.5 mg) once weekly and titrates up to 15 mg based on tolerance and glycemic goals. It is administered via subcutaneous injection alongside lifestyle changes.

Current incretin-based therapies (GLP-1 and GLP-1/GIP agonists) primarily reduce body weight through decreased food intake, but they fail to increase energy expenditure (EE) and often cause a compensatory drop in basal metabolic rate, which hinders sustainable weight loss.

If you are using GLP-1 medications like semaglutide or tirzepatide, expect significant weight loss primarily from eating less, not from burning more calories. Be aware that your body will likely slow down its resting metabolism as you lose weight, which can make maintaining loss difficult. This is a known biological adaptation, not a personal failure. Future treatments may combine appetite suppression with energy expenditure boosting to overcome this.

Hypoglycemia occurs in approximately 9% of GLP-1/GIP RA emergency exposures, a rate higher than previously reported, even in the absence of concomitant hypoglycemic medications.

Be aware that GLP-1 medications can cause low blood sugar, even if you aren't taking insulin. This is more likely if you skip meals, exercise heavily, or take a higher dose. Monitor your blood sugar if you feel shaky, dizzy, or confused, and treat lows with fast-acting carbohydrates.

Post-exercise consumption of 25g collagen hydrolysate or dairy protein does not improve indices of exercise-induced muscle damage (EIMD) or accelerate recovery compared to an isoenergetic placebo in recreationally active males.

If you are doing intense eccentric exercise (like downhill running), drinking 25g of collagen or dairy protein immediately after and for the next two days will not speed up your recovery or reduce soreness any more than drinking a placebo with the same calories. Focus on total daily protein intake and sleep rather than timing specific recovery supplements.

In older adults, visceral fat levels significantly decrease over two years, while body weight, muscle mass, and total body fat percentage do not change significantly.

As you age, your visceral fat may naturally decrease even if your weight and muscle mass stay the same. This highlights the importance of monitoring visceral fat, not just weight.

Bone Mineral Content (BMC) continues to decline during the weight regain phase (6-12 months) even when total body weight and fat mass are increasing.

If you lose a significant amount of weight (5% or more), your bone density may drop. This drop can continue even if you regain some of the weight later. To protect your bones, consider baseline bone density assessments if you are at risk (e.g., postmenopausal women) and ensure adequate calcium and vitamin D intake alongside resistance training.

Short-term overnutrition directly impairs thyroid hormone biosynthesis and peripheral T4-to-T3 conversion, causing hypothyroidism and reduced energy expenditure, despite compensatory thyroidal adaptations.

Obesity can directly damage thyroid function and slow metabolism, creating a vicious cycle. However, this damage is largely reversible with weight loss. Focus on sustainable caloric reduction rather than seeking thyroid fixes alone, as the thyroid dysfunction is a symptom of overnutrition, not the root cause.

Overnutrition reduces whole-body energy expenditure by impairing peripheral T4-to-T3 conversion via decreased D2 activity, rendering obese individuals resistant to T4 therapy.

Obesity impairs your body's ability to convert T4 into active T3, which lowers your metabolism and makes T4 supplements less effective for weight loss. The solution is not more thyroid medication, but weight loss, which restores normal thyroid function.

Off-label use of GLP-1 agonists by healthy athletes for aesthetic or performance purposes raises ethical, legal, and safety concerns, including potential classification as doping and inequality in sports access.

Using GLP-1 agonists off-label for aesthetic or performance reasons is not approved and carries ethical and legal risks. It may be viewed as doping and creates inequality in sports. Athletes should consult regulatory bodies and prioritize approved medical indications over off-label use for performance enhancement.

Genotype-based dietary interventions (low-carb vs. low-fat) do not significantly impact weight loss outcomes, suggesting that genotyping alone is not an effective precision medicine approach for weight loss.

Don't pay for expensive genetic testing to tell you whether to eat low-carb or low-fat. Current high-quality evidence shows that your genotype does not predict whether you will lose more weight on one diet versus the other. Focus on finding a dietary pattern you can adhere to consistently that creates a caloric deficit.

Tirzepatide administration (2.5-15 mg weekly) causes injection-site reactions (ISRs) in 2-8% of patients, presenting as localized erythema, swelling, or pruritus, which are generally mild, self-limiting, and comparable in frequency to other GLP-1 agonists.

Expect mild redness or itching at the injection site in the first few weeks. This is common and usually goes away on its own. Rotate your injection sites (abdomen, thigh, upper arm) and use clean needles to reduce irritation. If you get a rash that spreads or doesn't go away, contact your doctor.

Tirzepatide use is associated with rare but serious hypersensitivity reactions, including anaphylaxis and angioedema, occurring in approximately 1-4% of patients, often linked to anti-drug antibodies but not always causally related.

Watch for signs of a severe allergic reaction, such as swelling of the face/throat, difficulty breathing, or widespread hives. These are rare but serious. If you experience them, seek emergency medical help immediately. Most skin reactions are mild and go away on their own.

Excess and dysfunctional epicardial adipose tissue (EAT) contributes to coronary microvascular dysfunction (CMD) and vasospastic angina (VSA) through pro-inflammatory signaling, oxidative stress, and smooth muscle hyperreactivity.

If you have chest pain with normal arteries (CMD or VSA), reducing epicardial fat through lifestyle or medication may improve symptoms by lowering inflammation and improving blood vessel function.

GLP-1 receptor agonist utilization for obesity has increased significantly and disproportionately among women compared to men, with obesity emerging as a key predictor of use specifically in female patients.

If you are a woman with obesity, you are significantly more likely to be prescribed a GLP-1RA than a man with similar characteristics, particularly after 2021. This utilization gap is driven by stronger associations between obesity and prescription in women. Men should be aware that they may face lower prescription rates and should proactively discuss weight management options with their providers.